Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(117 products)
- EGFR(580 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(243 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(57 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2375 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Hypothemycin
CAS:Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.Formula:C19H22O8Purity:98%Color and Shape:SolidMolecular weight:378.37EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formula:C19H21N3O2SColor and Shape:SolidMolecular weight:355.45GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formula:C30H32N10O2Color and Shape:SolidMolecular weight:564.64FLT3-ITD-IN-3
CAS:FLT3-ITD-IN-3 (13v) is an orally active inhibitor of FLT3-ITD (internal tandem duplication of FLT3), which works by blocking FLT3 signaling. This inhibition leads to cell cycle arrest in the G0/G1 phase and induces apoptosis. The compound is currently employed in studies related to acute myeloid leukemia (AML).Formula:C27H21ClF2N6O5Color and Shape:SolidMolecular weight:582.943JAK1-IN-9
CAS:JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.Formula:C16H13IN6Color and Shape:SolidMolecular weight:416.22JAK-IN-23
"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."Formula:C23H22Cl2N4OColor and Shape:SolidMolecular weight:441.35FAK-IN-4
FAK-IN-4 (Compound 7d) has anticancer activities that can induce cell apoptosis. FAK-IN-4 is potential inhibitor of FAK [1].Formula:C20H22N4OColor and Shape:SolidMolecular weight:334.41(S)-3-Hydroxy Midostaurin
CAS:(S)-3-Hydroxy Midostaurin is a potent inhibitor of kinases(IC50 of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et)).Formula:C35H30N4O5Purity:98%Color and Shape:SolidMolecular weight:586.64HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formula:C28H26F3N7O3Color and Shape:SolidMolecular weight:565.55FAK-IN-2
FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.Formula:C28H31ClN8O3Color and Shape:SolidMolecular weight:563.05JNJ-47117096
CAS:JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.Formula:C21H22N4O2Color and Shape:SolidMolecular weight:362.425FGFR-IN-5
CAS:FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.Formula:C25H22N6O3Color and Shape:SolidMolecular weight:454.48Dual Cathepsin L/JAK-IN-1
CAS:DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Formula:C19H18ClN5Color and Shape:SolidMolecular weight:351.833JP-153
CAS:JP-153 is an inhibitor of Src-FAK-Paxillin signaling. It suppresses Src-dependent phosphorylation of paxillin (Y118) and subsequent activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation of retinal endothelial cells and is applicable in the study of neovascular eye diseases.Formula:C21H19NO5Color and Shape:SolidMolecular weight:365.379FAK-IN-23
CAS:FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).Formula:C32H38F3N5O8Color and Shape:SolidMolecular weight:677.668Protein kinase inhibitor 10
CAS:Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.Formula:C14H9FN6S2Color and Shape:SolidMolecular weight:344.39HER2-IN-21
CAS:HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.Formula:C20H18N4O3SColor and Shape:SolidMolecular weight:394.447HSN748
CAS:HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.Formula:C27H24F3N7OColor and Shape:SolidMolecular weight:519.521VEGFR/PDGFR-IN-1
CAS:VEGFR/PDGFR-IN-1 (Compound 1) is an inhibitor of VEGFR with an IC50 of 0.4 μM. It can inhibit angiogenesis in HUVEC cells and holds promise for impeding tumor growth and metastasis.Formula:C17H21N5O3Color and Shape:SolidMolecular weight:343.38TZEP7
CAS:TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.Formula:C27H19ClFNSColor and Shape:SolidMolecular weight:443.963WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formula:C26H22FN9O2Color and Shape:SolidMolecular weight:511.51FGFR1 inhibitor-17
CAS:FGFR1inhibitor-17 (Compound 92) is a potent inhibitor of FGFR1, with promising applications in cancer research.Formula:C16H13ClN2O3Color and Shape:SolidMolecular weight:316.739Protein kinase inhibitor 11
CAS:Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.Formula:C21H18FN5O2SColor and Shape:SolidMolecular weight:423.463EGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96TrxR/EGFR-IN-1
CAS:TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.Formula:C24H24AuClFN6O2PColor and Shape:SolidMolecular weight:710.878Tyrosine kinase-IN-9
CAS:Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.Formula:C20H14ClN3O3Color and Shape:SolidMolecular weight:379.796EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formula:C14H11BrN4O2SColor and Shape:SolidMolecular weight:379.23W23-1006
CAS:W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).Formula:C17H12BrN3O5Color and Shape:SolidMolecular weight:418.198Si306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formula:C25H26BrClN6OSColor and Shape:SolidMolecular weight:573.94FAK inhibitor 7
CAS:FAK inhibitor7, a potent FAK inhibitor, demonstrates an IC50 of 3.58 nM. This compound effectively inhibits downstream signaling cascades of FAK (such as Src and AKT), which leads to cell cycle arrest at the G0/G1 phase and induces cytotoxic autophagy in ovarian cancer cells. Additionally, FAK inhibitor7 has been shown to suppress tumor metastasis and growth in ovarian cancer mouse models.Formula:C32H37N7O3Color and Shape:SolidMolecular weight:567.68TGF-βRI inhibitor 3
CAS:TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.Formula:C21H21NO4Color and Shape:SolidMolecular weight:351.396lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formula:C25H26Cl2FN7O3Color and Shape:SolidMolecular weight:562.42FGFR1 inhibitor-16
CAS:FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.Formula:C16H9N5O3SColor and Shape:SolidMolecular weight:351.339FAK-IN-3
FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.Formula:C28H28N6O4Color and Shape:SolidMolecular weight:512.56ALK ligand-Linker Conjugate 1
CAS:ALK ligand-Linker Conjugate 1 is an ALK ligand-connector conjugate used for the synthesis of PROTACALK degrader-4.Formula:C36H45N5O3Color and Shape:SolidMolecular weight:595.77EGFR/VEGFR2-IN-3
CAS:EGFR/VEGFR2-IN-3 (compound 9) is an effective inhibitor of EGFR and VEGFR-2, demonstrating IC50 values of 0.129 µM for EGFR, 0.142 µM for VEGFR-2, and 3.428 µM for COX-2. This compound exhibits cytotoxic properties and induces cell apoptosis (apoptosis) as well as cell cycle arrest at the G2/M phase.Formula:C24H20ClN5O2S2Color and Shape:SolidMolecular weight:510.03Tandutinib sulfate
CAS:Tandutinib (MLN518) sulfate is an effective and selective inhibitor of FLT3, with an IC50 value of 0.22 μM. It also inhibits c-Kit and PDGFR, displaying IC50 values of 0.17 μM and 0.20 μM respectively. This compound can be utilized in the treatment of acute myeloid leukemia and has the capability to cross the blood-brain barrier.Formula:C31H44N6O8SColor and Shape:SolidMolecular weight:660.78Ten01
Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.Formula:C18H20F6N4OColor and Shape:SolidMolecular weight:422.37FGFR-IN-15
FGFR-IN-15 (compound 18i) acts as a pan-FGFR inhibitor, exhibiting potent inhibitory activity against FGFR1-4.Formula:C22H23N5O5SColor and Shape:SolidMolecular weight:469.51FGFR-IN-16
CAS:FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.Formula:C30H27Cl2N7O4Color and Shape:SolidMolecular weight:620.49UNC9750
CAS:UNC9750 is an inhibitor of inositol phosphate multikinase (IPMK), with IC50 values of 31.6 nM for IPMK and 374 nM for IP6K2. It effectively suppresses the accumulation of InsP5, a direct product of IPMK kinase activity, without affecting InsP6 or InsP7 levels. Additionally, UNC9750 inhibits over 75% of the activity of four kinases: DAPK1, DYRK1B, PDGFR, and KDR. This compound is applicable in glioblastoma research.Formula:C23H24N6OColor and Shape:SolidMolecular weight:400.48(3S,4R)-Tofacitinib
CAS:(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib is a JAK3 inhibitor(IC50 : 1 nM).Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37VEGFR-2-IN-26
CAS:VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.Formula:C24H19F3N6O2Color and Shape:SolidMolecular weight:480.44JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Formula:C26H36FN5O2Color and Shape:SolidMolecular weight:469.59EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Formula:C12H14N4OS2Color and Shape:SolidMolecular weight:294.4HPK1-IN-61
CAS:HPK1-IN-61 (Compound 1) serves as an inhibitor of hematopoietic progenitor kinase 1 (HPK1) with a Ki of 0.4 nM, and also inhibits Abl with an IC50 of less than 0.51 nM. Additionally, HPK1-IN-61 displays inhibitory activity against LCK, with an IC50 of 24 nM.Formula:C23H22N4O2Color and Shape:SolidMolecular weight:386.45Oxamic acid
CAS:Oxamic acid is an LDHA inhibitor, antitumor, induces apoptosis, downregulates EGFR expression, and inhibits cancer stem cell properties and EMT.Formula:C2H3NO3Color and Shape:SolidMolecular weight:89.05WZH-15-125
CAS:WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.Formula:C33H45BrN8O5SColor and Shape:SolidMolecular weight:745.73CEP-7055
CAS:CEP-18770: oral proteasome inhibitor; blocks NF-kappaB; may cause cancer cell apoptosis; less toxic than bortezomib in normal cells.Formula:C32H35N3O4Color and Shape:SolidMolecular weight:525.64Ifebemtinib tosylate
CAS:Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor with anti-tumor properties. It inhibits FAK autophosphorylation in prostate cancer cells and suppresses spheroid formation and in situ tumor growth in vivo. Ifebemtinib (tosylate) is applicable in cancer research, including studies on solid tumors, breast cancer, and malignant pleural mesothelioma.Formula:C35H36F4N6O7SColor and Shape:SolidMolecular weight:760.76EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formula:C27H19ClFN3OColor and Shape:SolidMolecular weight:455.91EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Color and Shape:SolidVatalanib hydrochloride
CAS:Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.Formula:C20H16Cl2N4Purity:99.7%Color and Shape:SolidMolecular weight:383.27NDI-034858
CAS:NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseasesFormula:C23H24N8O3Purity:>99.99%Color and Shape:SolidMolecular weight:460.49Vecabrutinib
CAS:Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.Formula:C22H24ClF4N7O2Purity:99.74%Color and Shape:SolidMolecular weight:529.92Ref: TM-T17220
1mg82.00€5mg177.00€10mg289.00€25mg470.00€50mg623.00€100mg874.00€1mL*10mM (DMSO)207.00€Zotizalkib
CAS:TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Formula:C21H20F3N5O3Purity:98.7%Color and Shape:SolidMolecular weight:447.41Ref: TM-T9414
1mg114.00€5mg268.00€10mg439.00€25mg879.00€50mg1,395.00€100mg1,873.00€1mL*10mM (DMSO)303.00€JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formula:C26H33N7OPurity:99.54%Color and Shape:SolidMolecular weight:459.59Ref: TM-T35900
1mg138.00€5mg334.00€10mg597.00€25mg1,234.00€50mg1,648.00€100mg2,232.00€1mL*10mM (DMSO)339.00€XMD-17-51 Trifluoroacetate
CAS:XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.Formula:C23H25F3N8O3Purity:99.65%Color and Shape:SolidMolecular weight:518.49JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formula:C28H39N3O3Color and Shape:SolidMolecular weight:465.63Ibrutinib Racemate
CAS:Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formula:C25H24N6O2Purity:98%Color and Shape:SolidMolecular weight:440.5(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37HMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Color and Shape:Odour LiquidDihydrodiol-Ibrutinib
CAS:PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formula:C25H26N6O4Color and Shape:SolidMolecular weight:474.521PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Color and Shape:Odour LiquidENMD-2076 tartrate
CAS:ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.Formula:C25H31N7O6Color and Shape:SolidMolecular weight:525.56TLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFormula:C16H15N5Color and Shape:Yellow SolidMolecular weight:277.331XMU-MP-3
CAS:XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.Formula:C27H27F3N8OColor and Shape:SolidMolecular weight:536.563Imbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Color and Shape:Odour LiquidNimotuzumab (powder)
CAS:Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Color and Shape:LiquidOlmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormula:C26H26N6O2SPurity:99.14%Color and Shape:SolidMolecular weight:486.59Desidustat
CAS:Desidustat is an inhibitor of HIF hydroxylase.
Formula:C16H16N2O6Purity:98%Color and Shape:SolidMolecular weight:332.31Duligotuzumab
CAS:Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Purity:95%Color and Shape:LiquidRef: TM-T80604
Discontinued product3,3',4,4'-Tetrabromobiphenyl
CAS:Controlled ProductApplications 3,3',4,4'-Tetrabromobiphenyl is multi-persistent organic pollutants analyzed in breast milk of first time mothers. An environmental pollutant that affects copper and molybdenum metabolism in rats. Also, it is derived from 1-Bromo-2- nitrobenze (B686175), which is an organic building block used for the synthesis of various pharmaceutical compounds. It is an intermediate for the synthesis of novel Diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
References Tlustos, C., et al.: Organohalogen Compd., 75, 1185-1188 (2013); Salman, K. N., et al.: Environ. Sci. Pollut. R., 21, 6400-6409 (2014); Dao, P., et al.: Bioorg. Med. Chem. Lett., 23, 4552 (2013);Formula:C12H6Br4Color and Shape:Off-White To Light BrownMolecular weight:469.79VEGFR-IN-1
CAS:VEGFR inhibitorFormula:C19H16ClN3OPurity:98%Color and Shape:SolidMolecular weight:337.8
